Zevra (ZVRA) Q2 FY26 earnings call

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Zevra Therapeutics delivered strong Q2 FY26 results, driven by robust U.S. commercial performance of MIPLYFFA and continued pipeline progress for celiprolol. The company is actively pursuing a reexamination process with the CHMP for arimoclomol following a negative opinion, while maintaining patient access through its Expanded Access Program. Management emphasizes disciplined capital allocation to support growth and pipeline advancement.

You’re reading a preview. Opening the full call uses 1 concall credit.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.